Bristol Myers Squibb Reports Three-Year CheckMate-9LA Data for Opdivo Plus Yervoy in NSCLC

Bristol Myers Squibb today presented three-year overall survival data from the Phase 3 CheckMate-9LA trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) with two cycles of chemotherapy versus four cycles of chemotherapy in patients with previously untreated metastatic non-small cell lung cancer. The data showed that 20% of patients in the Opdivo plus Yervoy arm were alive at three years compared to 12% in the chemotherapy arm.